![5](https://www.srjnews.com/wp-content/uploads/2015/06/5.jpg)
AbbVie Inc. (NYSE:ABBV) released that EC has approved marketing endorsement for IMBRUVICA (ibrutinib) for the treatment of Waldenstrom’s macroglobulinemia, a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. AbbVie said the approval triggers a $20 million milestone payment from Janssen. Pharmacyclics LLC, an AbbVie company, received FDA approval for IMBRUVICA for the treatment of Waldenstrom’s macroglobulinemia in the U.S., in January 2015. Shares of AbbVie Inc. (NYSE:ABBV) traded at $69.23 by surging 1.85% with price volatility of 1.75% for a week and 1.81% for a month.
JDS Uniphase Corporation (NASDAQ:JDSU) announced on Friday that it continues to anticipate to spin off its communications as well as commercial optical products or CCOP business into a separate, publicly-traded company, Lumentum Holdings Inc., in the third calendar quarter of 2015. Existing filings with the Securities and Exchange Commission indicate a distribution date of July 26. JDSU is continuing the customary regulatory process, and is targeting a revised separation date in August. The company will confirm definitive separation, record and distribution dates once the regulatory process is completed. JDS Uniphase Corporation (NASDAQ:JDSU) stock has highest price of $11.18 in last session, beginning with a price of $11.17 and reported an increase of 0.45% to close at $11.09 with a day range of $11.04-$11.18. The stock is going forward its 52-week low with 4.43% and moving down from its 52 week high price with -22.18%.
Henry Schein, Inc. (NASDAQ:HSIC) [Trend Analysis] released that it has made a 50% ownership investment in Maravet, an animal health distributor in Romania. Henry Schein’s investment in Maravet adds to the firm’s Eastern European presence. Maravet is a privately-held company with annual sales of approximately $23 million. Maravet was founded by the Korponay family, which retains a 50 percent ownership position in the company. Henry Schein, Inc. (NASDAQ:HSIC) stock hit highest price at $145.92, beginning with a price of $144.98 and reported a gain of 1.42% to close at $145.47 with a day range of $144.29-$145.92. The total market capitalization remained 12.16 Billion, total volume of 293191 shares held in the session was surprisingly higher than its average volume of 432.02 shares.